Skip to main content
. Author manuscript; available in PMC: 2020 Jun 12.
Published in final edited form as: Hum Brain Mapp. 2019 Oct 21;41(3):767–778. doi: 10.1002/hbm.24838

FIGURE 5.

FIGURE 5

The relationships between effect sizes of ketamine (a), midazolam (b), and their difference (c) versus network-based patient-control differences in schizophrenia. Subplot (d) represents the relationship between the effect sizes of midazolam versus the effect sizes of ketamine (positive, but nonsignificant). We observed a significant positive correlation with effect sizes for ketamine–midazolam contrast (c); tending to significant positive correlation for ketamine (a), and no correlation for midazolam (b) with the effect sizes in schizophrenia